Illustrative image – not actual.Sun Pharma intends to invest on research and development (R&D) during the FY12.
The company has earmarked Rs 450 crore for the purpose. The capex plan will be for Sun, its United States subsidiary Caraco Pharmaceutical Laboratories and Israeli drug-maker Taro, which was acquired in September 2010.
Meanwhile, the company is keen on acquisition opportunities in the US and is scouting for the same.
